{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:09:01Z","timestamp":1757617741800,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008067","name":"Genomic Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The 21-gene Breast Recurrence Score\u00ae (Oncotype DX\u00ae) assay has improved the selection of patients for chemotherapy in early breast cancer. Internationally, this test is used in lymph node positive disease, but at the time this study was conducted, it was not reimbursed for this indication in Ireland.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>Determine how access to the Recurrence Score\u00ae testing reduces chemotherapy use and quantifies the impact on oncologists\u2019 treatment recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between March and September 2017, 75 patients were enrolled in a prospective study across ten hospitals. Eligible patients had oestrogen\/progesterone receptor positive and HER2 negative breast cancer with 1\u20133 involved lymph nodes. Following informed consent, demographics were collected and questionnaires completed by a consultant medical oncologist before and after the recurrence score testing, which examined expectations of tumour chemosensitivity, strength of chemotherapy recommendation, and planned treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Recurrence Scores\u00ae were available on 74\/75 patients. Overall, access to this test led to a 27% reduction in the recommendation for chemotherapy from 68 (92%) to 48 (65%) patients. This was most notable in patients with one (46 versus 34 patients) and two (13 versus seven patients) involved lymph nodes representing a 26% and 46% reduction, respectively. The reduction in chemotherapy use was marked in women aged 50\u201370\u00a0years with one lymph node involved (28 versus 18 patients)\u2014a 36% reduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Consistent with our hypothesis, broader access to the Recurrence Score\u00ae led to a reduction in the use of chemotherapy in Ireland and has subsequently become standard of care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11845-025-03922-7","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:12:34Z","timestamp":1744344754000},"page":"839-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CTRIAL-IE (ICORG) 15\u201334: The impact of the 21 gene breast recurrence score\u00ae assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland"],"prefix":"10.1007","volume":"194","author":[{"given":"W. J.","family":"Mullally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"McSorley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Walshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Coate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Milewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. S.","family":"Breathnach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. T.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"2","key":"3922_CR1","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69\u201390","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3922_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-015-3555-4","volume":"153","author":"L Smyth","year":"2015","unstructured":"Smyth L, Watson G, Walsh EM et al (2015) Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. Breast Cancer Res Treat 153(3):573\u2013582","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3922_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2012.09.003","volume":"34","author":"SD Ramsey","year":"2013","unstructured":"Ramsey SD, Barlow WE, Gonzalez-Angulo AM et al (2013) Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34(1):1\u20139","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"3922_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/annonc\/mds512","volume":"24","author":"W Eiermann","year":"2013","unstructured":"Eiermann W, Rezai M, Kummel S et al (2013) The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 24(3):618\u2013624","journal-title":"Ann Oncol"},{"issue":"3","key":"3922_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5694\/mja12.11334","volume":"199","author":"RH de Boer","year":"2013","unstructured":"de Boer RH, Baker C, Speakman D et al (2013) The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Med J Aust 199(3):205\u2013208","journal-title":"Med J Aust"},{"issue":"2","key":"3922_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JOP.2010.000046","volume":"7","author":"R Oratz","year":"2011","unstructured":"Oratz R, Kim B, Chao C et al (2011) Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 7(2):94\u201399","journal-title":"J Oncol Pract"},{"issue":"2","key":"3922_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant Chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"25","key":"3922_CR8","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336\u20132347","journal-title":"N Engl J Med"},{"issue":"8","key":"3922_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.2014-0467","volume":"20","author":"J Gligorov","year":"2015","unstructured":"Gligorov J, Pivot XB, Jacot W et al (2015) Prospective clinical utility study of the use of the 21-gene assay in adjuvant clinical decision making in women with estrogen receptor-positive early invasive breast cancer: results from the SWITCH study. Oncologist 20(8):873\u2013879","journal-title":"Oncologist"},{"issue":"20","key":"3922_CR10","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","volume":"34","author":"O Gluz","year":"2016","unstructured":"Gluz O, Nitz UA, Christgen M et al (2016) West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341\u20132349","journal-title":"J Clin Oncol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03922-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:49:05Z","timestamp":1757155745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03922-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3922"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03922-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted approval by Cancer Trials Ireland, and was approved locally by Individual Hospital Ethics committee. The study was performed in accordance with the ethical standards as laid down in the\u00a01964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This was obtained prospectively as per patient enrolment in CTRIAL-IE 15\u201334. (ICORG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"PG Morris\u2014Honoraria: Genomic Health, Inc. All other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}